These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9592392)

  • 1. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.
    Chase M; Chung RY; Chiocca EA
    Nat Biotechnol; 1998 May; 16(5):444-8. PubMed ID: 9592392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
    Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
    Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus.
    Pawlik TM; Nakamura H; Yoon SS; Mullen JT; Chandrasekhar S; Chiocca EA; Tanabe KK
    Cancer Res; 2000 Jun; 60(11):2790-5. PubMed ID: 10850415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
    Ichikawa T; Petros WP; Ludeman SM; Fangmeier J; Hochberg FH; Colvin OM; Chiocca EA
    Cancer Res; 2001 Feb; 61(3):864-8. PubMed ID: 11221871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.
    Aghi M; Chou TC; Suling K; Breakefield XO; Chiocca EA
    Cancer Res; 1999 Aug; 59(16):3861-5. PubMed ID: 10463570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
    Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
    Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
    Wei MX; Tamiya T; Rhee RJ; Breakefield XO; Chiocca EA
    Clin Cancer Res; 1995 Oct; 1(10):1171-7. PubMed ID: 9815909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
    Chen L; Yu LJ; Waxman DJ
    Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
    Fu X; Tao L; Cai R; Prigge J; Zhang X
    Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
    Chen CS; Jounaidi Y; Waxman DJ
    Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
    Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
    Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy.
    Günther M; Waxman DJ; Wagner E; Ogris M
    Cancer Gene Ther; 2006 Aug; 13(8):771-9. PubMed ID: 16543915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
    Tyminski E; Leroy S; Terada K; Finkelstein DM; Hyatt JL; Danks MK; Potter PM; Saeki Y; Chiocca EA
    Cancer Res; 2005 Aug; 65(15):6850-7. PubMed ID: 16061668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
    Herrlinger U; Woiciechowski C; Sena-Esteves M; Aboody KS; Jacobs AH; Rainov NG; Snyder EY; Breakefield XO
    Mol Ther; 2000 Apr; 1(4):347-57. PubMed ID: 10933953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses.
    Li H; Zeng Z; Fu X; Zhang X
    Cancer Res; 2007 Aug; 67(16):7850-5. PubMed ID: 17699791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.
    Nakamura H; Mullen JT; Chandrasekhar S; Pawlik TM; Yoon SS; Tanabe KK
    Cancer Res; 2001 Jul; 61(14):5447-52. PubMed ID: 11454690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model.
    Cullinan AE; Lindstrom MJ; Sabet S; Albert DM; Brandt CR
    Curr Eye Res; 2004; 29(2-3):167-72. PubMed ID: 15512963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.